T2 Biosystems COVID-19 Molecular Test Can Detect Mu, Iota Variants

 

• T2 Biosystems Inc (NASDAQ: TTOO) announced that its T2SARS-CoV-2 Panel is capable of detecting the Mu (B.1.621) and Iota (B.1.526) variants, which were recently confirmed to be present in the U.S.

• The T2SARS-CoV-2 Panel, which has demonstrated clinical sensitivity of 95% and specificity of 100%, provides results in under two hours utilizing an upper respiratory swab sample.

• The test runs on the Company's T2Dx Instrument, which can perform seven tests simultaneously and up to sixty samples per day.

• The same T2Dx Instrument is also capable of running the FDA-cleared T2Bacteria Panel and T2Candida Panel.

• These panels are the only FDA-cleared assays for detecting sepsis-causing bacterial and fungal pathogens directly from whole blood in three to five hours, without the need to wait days for blood culture results.

https://finance.yahoo.com/news/t2-biosystems-stock-jumps-covid-104732844.html